Dr. Ari S. Kellen, M.D. – Director
Medical Doctor, University of Witwatersrand | MBA, University of Witwatersrand
Dr. Ari Kellen is a seasoned senior executive with over three decades of healthcare industry experience, both in management consulting and in major global P&L operational roles. Dr. Kellen trained and worked as a physician in South Africa while also running a large segment of a 1,000 bed teaching hospital. After being recruited by McKinsey & Company, he spent 23 years serving healthcare clients around the world. Dr. Kellen served for more than a decade as a Senior Partner at McKinsey, advising CEOs and Board members at large industry-leading healthcare companies and small rapidly growing entities. His experience spans biotechnology, medical device, payor and provider organizations, and includes work focused on M&A, business development, new company spin-outs, corporate and business unit level turnarounds, R&D portfolio strategy, and product / therapeutic area growth strategies. In 2014, Dr. Kellen was recruited to Bausch + Lomb / Valeant where he ran a multi-billion dollar P&L across the US and Latin America. As EVP and General Manager of US Bausch + Lomb, he successfully launched and commercialized new products in Pharmaceuticals, Surgical, and Vision Care / Contact Lenses. Dr. Kellen was also responsible for leading the United States R&D organization to advance more than 100 active R&D projects across Dermatology, Ophthalmology, Gastroenterology, Oncology and Consumer Products. Dr. Kellen currently serves on the Advisory Boards of Paragon Biosciences and Castle Creek Pharmaceuticals.
Dr. Saeid Babaei, PhD – Chairman
PhD, Immunology, U of Toronto | Executive MBA, University of Toronto
Dr. Babaei has over 20 years of experience in leadership roles in the biopharmaceutical industry. He is currently President, & CEO of AbCelex Technologies with a proprietary antibody-based platform technology for animal health and human diagnostics. Prior to AbCelex, Dr. Babaei has served as Vice President of Business Development at Aptose Biosciences where he played a key role in a broad range of activities including establishing joint ventures, obtaining private financings, investor relations, and business development. He successfully negotiated a partnership deal for Virulizin, a cancer immunotherapy product candidate to Zor Pharmaceuticals, a subsidiary of Zoticon Bioventures. Previously, Dr. Babaei’s served as Director of Corporate Development at Northern Therapeutics Inc, a biopharmaceutical company which develops novel cell and gene therapies, where he was instrumental in launching the ‘first’ cell-based gene therapy clinical trial for patients with pulmonary arterial hypertension. He played key roles in obtaining financings, and in securing a partnership deal with United Therapeutics. Dr. Babaei currently serves as Chairman of the Board for BriaCell Therapeutics, an immuno-oncology biotech focused on late-stage breast cancer.
Mr. Isaac B. Maresky – CEO and Director
Mr. Isaac Maresky is a serial entrepreneur and investment banking professional with hundreds of millions of dollars of financings and M&A experience. He co-founded another successful immunotherapy company alongside a veteran oncologist and cancer-vaccine pioneer, and led its go-public, subsequently joining Vaxil as apart of its restructuring efforts in an effort to advance its pipeline of innovative cancer therapies.
Mr. Maresky is a Principal with Sunel Securities investment bank, which also acts as a private equity firm investing substantially in its transactions. At Sunel, he focuses on identifying and executing unique and attractive investment opportunities for the firm and its investors. In that regard, Mr. Maresky has visited, analyzed, and conducted in-depth diligence on assets and investment opportunities in several countries around the globe.
Mr. Maresky began his career at the Royal Bank of Canada in its Wealth Management Group known as Dominion Securities where he was the #1 performing intern of his year. Subsequently, he worked as an Investment Banking Analyst for a British Multinational Bank specializing in large M&A advisory.
Dr. Shawn Langer, M.D. – Director
Dr. Shawn Langer brings over two decades of healthcare industry experience. Dr. Langer was Senior Partner at McKinsey & Company, where he was the leader of its Healthcare Private Equity Group.
During his 15 years with McKinsey & Company, Dr. Langer served healthcare clients across pharmaceuticals, biotechnology, medical devices, and healthcare services.
Most recently Dr. Langer has spent nearly 5 years investing in innovative healthcare companies in his capacity as a portfolio manager at healthcare private equity investment firm BMHS Investments.
Mr. Gadi Levin – CFO and Director
B.Commerce | Chartered Accountant | MBA
Mr. Levin is an accountant with clinical-stage biotech experience through another position held as Chief Financial Officer of a breast cancer immunotherapy focused firm.
Mr. Levin Most recently, acted as Chief Financial Officer of Labstyle Innovations Ltd, a biotechnology company focused on diabetes. Mr. Levin served as the Vice President of Finance and Chief Financial Officer for two Israeli investment houses in the fields of private equity, hedge funds and real estate (2008 to 2009 and 2010, respectively). Prior to that, Mr. Levin acted as Financial Consultant to various firms.
Mr. Levin began his career at the former “Big Five” accounting firm Arthur Andersen, where he worked in the Cape Town, London, and Tel Aviv offices for nine years. He holds a Bachelor of Commerce degree in Accounting and Information Systems from the University of the Cape Town, South Africa, and a Post-Grad in Accounting from the University of South Africa. He received his Chartered Accountant designation in South Africa and has an MBA from Bar Ilan University in Israel.